168 related articles for article (PubMed ID: 17368733)
1. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract][Full Text] [Related]
2. Targeting mTOR signaling in lung cancer.
Marinov M; Fischer B; Arcaro A
Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
4. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
5. Targeting phosphoinositide 3-kinase signalling in lung cancer.
Wojtalla A; Arcaro A
Crit Rev Oncol Hematol; 2011 Nov; 80(2):278-90. PubMed ID: 21316260
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
7. The role of new targeted therapies in small-cell lung cancer.
Rossi A; Maione P; Colantuoni G; Guerriero C; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):45-53. PubMed ID: 15207253
[TBL] [Abstract][Full Text] [Related]
8. [Research advance on molecular and cellular biology of small cell lung cancer].
Ji FY; Qian GS; Huang GJ
Ai Zheng; 2005 Jul; 24(7):903-8. PubMed ID: 16004825
[TBL] [Abstract][Full Text] [Related]
9. Peptide hormones and lung cancer.
Moody TW
Panminerva Med; 2006 Mar; 48(1):19-26. PubMed ID: 16633328
[TBL] [Abstract][Full Text] [Related]
10. The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment.
Sato T; Gotoh N
Expert Opin Ther Targets; 2009 Jun; 13(6):689-700. PubMed ID: 19456272
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of novel treatment strategies.
Giaccone G
Oncogene; 2002 Oct; 21(45):6970-81. PubMed ID: 12362278
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
13. [Insulin-like growth factor (IGF)-signalling pathway components are potential therapeutic targets in the treatment of human hepatocellular carcinoma].
Nussbaum T; Samarin J; Schirmacher P; Breuhahn K
Verh Dtsch Ges Pathol; 2007; 91():278-85. PubMed ID: 18314625
[TBL] [Abstract][Full Text] [Related]
14. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
Doepfner KT; Boller D; Arcaro A
Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
[TBL] [Abstract][Full Text] [Related]
15. [Drug therapy for small-cell lung cancer (SCLC)--new molecular strategies for therapy].
Brückl WM; Lampert S; Zirlik S; Hahn EG; Wiest GH
Pneumologie; 2008 Jan; 62(1):23-30. PubMed ID: 17948174
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
18. The potential role of mTOR inhibitors in non-small cell lung cancer.
Gridelli C; Maione P; Rossi A
Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
20. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion.
Song P; Sekhon HS; Lu A; Arredondo J; Sauer D; Gravett C; Mark GP; Grando SA; Spindel ER
Cancer Res; 2007 Apr; 67(8):3936-44. PubMed ID: 17440109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
